liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
Olsson, Anders
Alternative names
Publications (10 of 188) Show all publications
Olsson, A. (2021). Triglyceridrika lipoproteiner – farligare än LDL-kolesterol?: Hög kolesterolhalt i triglyceridrika lipoproteiner tycks gynna uppkomsten av aterosklerotisk kardiovaskulär sjukdom [Are triglyceride rich lipoproteins more dangerous than LDL cholesterol?]. Läkartidningen, 118
Open this publication in new window or tab >>Triglyceridrika lipoproteiner – farligare än LDL-kolesterol?: Hög kolesterolhalt i triglyceridrika lipoproteiner tycks gynna uppkomsten av aterosklerotisk kardiovaskulär sjukdom [Are triglyceride rich lipoproteins more dangerous than LDL cholesterol?]
2021 (English)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 118Article in journal (Other academic) Published
Abstract [en]

Two prospective epidemiological studies have pointed to the importance of triglyceride rich lipoproteins in causing atherosclerosis. Lipoprotein analyses show that it is the cholesterol content of the lipoproteins that relates to atherosclerotic cardiovascular disease. As high blood levels of these lipoproteins are mostly seen in obese people changes in lifestyle seem to be the most relevant therapeutic measure.

Abstract [sv]

Två epidemiologiska studier har visat påbetydelsen av triglyceridrika lipoproteinerför uppkomst av aterosklerotisk kardiovaskulär sjukdom.

Lipoproteinanalyser visar att det ärkolesterolhalten i dessa triglyceridrika lipoproteiner som synes gynna uppkomstenav aterosklerotisk kardiovaskulär sjukdom.

Då förhöjning av dessa lipoproteinerfrämst ses vid övervikt är livsstilsförändringar av särskild betydelse i förebyggandesyfte.

Place, publisher, year, edition, pages
Sveriges Läkarförbund, 2021
National Category
Nutrition and Dietetics
Identifiers
urn:nbn:se:liu:diva-185091 (URN)33997946 (PubMedID)
Available from: 2022-05-17 Created: 2022-05-17 Last updated: 2022-06-10Bibliographically approved
Salahuddin, T., Kittelson, J., Tardif, J.-C., Shah, P. K., Olsson, A., Nicholls, S. J., . . . Schwartz, G. G. (2020). Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. American Heart Journal, 221, 60-66
Open this publication in new window or tab >>Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial
Show others...
2020 (English)In: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 221, p. 60-66Article in journal (Refereed) Published
Abstract [en]

Background High-density lipoprotein cholesterol (HDL-C) concentration is inversely related to risk of major adverse cardiovascular events (MACE) in epidemiologic studies but is a poorer predictor of MACE in patients with established coronary heart disease. HDL particle concentration (HDLP) has been proposed as a better predictor of risk. We investigated whether HDLP is associated with risk of MACE after acute coronary syndrome (ACS). Methods The dal-Outcomes trial compared the CETP inhibitor dalcetrapib with placebo in patients with recent ACS. In a nested case-cohort analysis, total, large, medium, and small HDLPs were measured by nuclear magnetic resonance spectroscopy at baseline (4-12 weeks after ACS) in 476 cases with MACE and 902 controls. Hazard ratios (HRs; case-control) for 1-SD increment of HDLP or HDL-C at baseline were calculated with and without adjustment for demographic, clinical, laboratory, and treatment variables. Similarly, HRs for MACE were calculated for changes in HDLP or HDL-C from baseline to month 3 of assigned treatment. Results Over median follow-up of 28 months, the risk of MACE was not associated with baseline HDLP (adjusted HR = 0.98, 95% CI = 0.84-1.15, P =.81), any HDLP subclass, or HDL-C. Dalcetrapib increased HDL-C and total, medium, and large HDLP and decreased small HDLP but had no effect on MACE compared with placebo. There were no association of risk of MACE with change in HDLP or HDL-C and no interaction with assigned study treatment. Conclusions Neither baseline HDLP nor the change in HDLP on treatment with dalcetrapib or placebo was associated with risk of MACE after ACS.

Place, publisher, year, edition, pages
MOSBY-ELSEVIER, 2020
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-164029 (URN)10.1016/j.ahj.2019.12.003 (DOI)000512980500007 ()31927126 (PubMedID)
Available from: 2020-03-04 Created: 2020-03-04 Last updated: 2021-05-01
White, H., Gabriel, S. P., Szarek, M., Bhatt, D., Bittner, V., Diaz, R., . . . ODYSSEY, O. I. (2019). Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 40(33), 2801-2809
Open this publication in new window or tab >>Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial
Show others...
2019 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 40, no 33, p. 2801-2809Article in journal (Refereed) Published
Abstract [en]

Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (=1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Place, publisher, year, edition, pages
Oxford University Press, 2019
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-162037 (URN)10.1093/eurheartj/ehz299 (DOI)000490154300015 ()31121022 (PubMedID)2-s2.0-85070265173 (Scopus ID)
Available from: 2019-11-18 Created: 2019-11-18 Last updated: 2020-01-09
Olsson, A. (2019). PCSK9-hämmare kan minska total dödlighet: Resultat och konsekvenser av ODYSSEY-studien. Läkartidningen, 116
Open this publication in new window or tab >>PCSK9-hämmare kan minska total dödlighet: Resultat och konsekvenser av ODYSSEY-studien
2019 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 116Article in journal, Editorial material (Other academic) Published
Abstract [sv]

ODYSSEY-studien visar att subkutan injektion av 75–150 mg alirokumab var 14:e dag, som tillåter deltagare att nå LDL-kolesterol på 0,4 mmol/l, minskar risk för det primära effektmåttet kranskärlsdöd, akut hjärtinfarkt, sjukhusvård för instabil angina pectoris eller ischemisk stroke med 15 procent.

Under samma förutsättningar visar studien också att risken för total dödlighet minskar med 15 procent.

Behandlingen var säker och tolererbar under hela studien.

Abstract [en]

The ODYSSEY outcome study, including subjects with recent acute coronary syndrome on high dose statin therapy, investigated the effect of 75-150 mg alirocumab given subcutaneously every 2 weeks for 2,8 years in comparison with participants on alirocumab placebo Alirocumab decreased the risk of the primary endpoint coronary death, acute myocardial infarction, hospital admittance because of angina pectoris and ischaemic stroke by 15 percent, decreased the risk of total death by 15 percent and was safe and tolerable during the length of the study.

Place, publisher, year, edition, pages
Stockholm, Sweden: Läkartidningen förlag AB, 2019
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-165426 (URN)
Available from: 2020-05-01 Created: 2020-05-01 Last updated: 2020-05-06Bibliographically approved
Rosenson, R. S., Larrey, D., Waters, D. D. & Olsson, A. (2018). Comments: Praluent (Alirocumab)-Induced Renal Injury. Journal of Pharmacy Practice, 31(2), 138-139
Open this publication in new window or tab >>Comments: Praluent (Alirocumab)-Induced Renal Injury
2018 (English)In: Journal of Pharmacy Practice, ISSN 0897-1900, E-ISSN 1531-1937, Vol. 31, no 2, p. 138-139Article in journal, Editorial material (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Sage Publications, 2018
Keywords
acute renal injury; alirocumab; rosuvastatin
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-155854 (URN)10.1177/0897190017734429 (DOI)000429881200001 ()28974137 (PubMedID)2-s2.0-85043371282 (Scopus ID)
Available from: 2019-03-29 Created: 2019-03-29 Last updated: 2019-10-24Bibliographically approved
Pitts, R., Gunzburger, E., Ballantyne, C. M., Barter, P. J., Kallend, D., Leiter, L. A., . . . Schwartz, G. G. (2017). Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6(1), Article ID e004119.
Open this publication in new window or tab >>Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure
Show others...
2017 (English)In: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, ISSN 2047-9980, E-ISSN 2047-9980, Vol. 6, no 1, article id e004119Article in journal (Refereed) Published
Abstract [en]

Background- Aldosterone may have adverse effects in the myocardium and vasculature. Treatment with an aldosterone antagonist reduces cardiovascular risk in patients with acute myocardial infarction complicated by heart failure (HF) and left ventricular systolic dysfunction. However, most patients with acute coronary syndrome do not have advanced HF. Among such patients, it is unknown whether aldosterone predicts cardiovascular risk. Methods and Results- To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome. Patients with New York Heart Association class II (with LVEF amp;lt; 40%), III, or IV HF were excluded. Aldosterone was measured at randomization in 4073 patients. The primary outcome was a composite of coronary heart disease death, nonfatal myocardial infarction, stroke, hospitalization for unstable angina, or resuscitated cardiac arrest. Hospitalization for HF was a secondary endpoint. Over a median follow-up of 37 months, the primary outcome occurred in 366 patients (9.0%), and hospitalization for HF occurred in 72 patients (1.8%). There was no association between aldosterone and either the time to first occurrence of a primary outcome (hazard ratio for doubling of aldosterone 0.92, 95% confidence interval 0.78-1.09, P=0.34) or hospitalization for HF (hazard ratio 1.38, 95% CI 0.96-1.99, P=0.08) in Cox regression models adjusted for covariates. Conclusions- In patients with recent acute coronary syndrome but without advanced HF, aldosterone does not predict major cardiovascular events.

Place, publisher, year, edition, pages
WILEY-BLACKWELL, 2017
Keywords
acute coronary syndrome; aldosterone; morbidity/mortality
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-135708 (URN)10.1161/JAHA.116.004119 (DOI)000393593300008 ()28073769 (PubMedID)
Note

Funding Agencies|F. Hoffmann-La Roche

Available from: 2017-03-17 Created: 2017-03-17 Last updated: 2018-04-16
Olsson, A., Angelin, B., Assmann, G., Binder, C. J., Bjoerkhem, I., Cedazo-Minguez, A., . . . Yvan-Charvet, L. (2017). Can LDL cholesterol be too low? Possible risks of extremely low levels. Journal of Internal Medicine, 281(6), 534-553
Open this publication in new window or tab >>Can LDL cholesterol be too low? Possible risks of extremely low levels
Show others...
2017 (English)In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 281, no 6, p. 534-553Article, review/survey (Refereed) Published
Abstract [en]

Following the continuous accumulation of evidence supporting the beneficial role of reducing low-density lipoprotein cholesterol (LDL-C) levels in the treatment and prevention of atherosclerotic cardiovascular disease and its complications, therapeutic possibilities now exist to lower LDL-C to very low levels, similar to or even lower than those seen in newborns and nonhuman species. In addition to the important task of evaluating potential side effects of such treatments, the question arises whether extremely low LDL-C levels per se may provoke adverse effects in humans. In this review, we summarize information from studies of human cellular and organ physiology, phenotypic characterization of rare genetic diseases of lipid metabolism, and experience from clinical trials. Specifically, we emphasize the importance of the robustness of the regulatory systems that maintain balanced fluxes and levels of cholesterol at both cellular and organismal levels. Even at extremely low LDL-C levels, critical capacities of steroid hormone and bile acid production are preserved, and the presence of a cholesterol blood-brain barrier protects cells in the central nervous system. Apparent relationships sometimes reported between less pronounced low LDL-C levels and disease states such as cancer, depression, infectious disease and others can generally be explained as secondary phenomena. Drug-related side effects including an increased propensity for development of type 2 diabetes occur during statin treatment, whilst further evaluation of more potent LDL-lowering treatments such as PCSK9 inhibitors is needed. Experience from the recently reported and ongoing large event-driven trials are of great interest, and further evaluation including careful analysis of cognitive functions will be important. This is an article from the symposium: Risks and benefits of Extremely Low LDL Cholesterol.

Place, publisher, year, edition, pages
WILEY, 2017
Keywords
abetalipoproteinaemia; adverse effects; hypocholesterolaemia; low-density lipoprotein; safety
National Category
Other Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-138220 (URN)10.1111/joim.12614 (DOI)000401715800001 ()28295777 (PubMedID)
Note

Funding Agencies|Foundation of Old Servants; International Task Force for The Prevention of Cardiometabolic Diseases

Available from: 2017-06-14 Created: 2017-06-14 Last updated: 2018-04-16
Schwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., . . . Olsson, A. (2015). Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. Journal of the American College of Cardiology, 65(21), 2267-2275
Open this publication in new window or tab >>Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
Show others...
2015 (English)In: Journal of the American College of Cardiology, ISSN 0735-1097, E-ISSN 1558-3597, Vol. 65, no 21, p. 2267-2275Article in journal (Refereed) Published
Abstract [en]

BACKGROUND Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins. It is uncertain whether triglycerides predict risk after ACS on a background of statin treatment. OBJECTIVES This study examined the relationship of fasting triglyceride levels to outcomes after ACS in patients treated with statins. METHODS Long-term and short-term relationships of triglycerides to risk after ACS were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively. Analysis of dal-OUTCOMES included 15,817 patients (97% statin-treated) randomly assigned 4 to 12 weeks after ACS to treatment with dalcetrapib (a cholesteryl ester transfer protein inhibitor) or placebo and followed for a median 31 months. Analysis of MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS and followed for 16 weeks. Fasting triglycerides at initial random assignment were related to risk of coronary heart disease death, nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass index. RESULTS Fasting triglyceride levels were associated with both long-term and short-term risk after ACS. In dalOUTCOMES, long-term risk increased across quintiles of baseline triglycerides (p less than 0.001). The hazard ratio in the highest/lowest quintile (greater than 175/less than= 80 mg/dl) was 1.50 (95% confidence interval: 1.05 to 2.15). There was no interaction of triglycerides and treatment assignment on the primary outcome. In the atorvastatin group of MIRACL, short-term risk increased across tertiles of baseline triglycerides (p = 0.03), with a hazard ratio of 1.51 (95% confidence interval: 1.05 to 2.15) in highest/lowest tertiles (greater than195/less than= 135 mg/dl). The relationship of triglycerides to risk was independent of lowdensity lipoprotein cholesterol in both studies. CONCLUSIONS Among patients with ACS treated effectively with statins, fasting triglycerides predict long-term and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy. (C) 2015 by the American College of Cardiology Foundation.

Place, publisher, year, edition, pages
Elsevier, 2015
Keywords
lipids; myocardial infarction; unstable angina
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-119573 (URN)10.1016/j.jacc.2015.03.544 (DOI)000355196300001 ()26022813 (PubMedID)
Note

Funding Agencies|F. Hoffmann-La Roche Ltd.; Pfizer; Anthera; Resverlogix; Roche; Sanofi; Amgen; AstraZeneca; Karobio; Merck

Available from: 2015-06-23 Created: 2015-06-22 Last updated: 2017-12-04
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., . . . Gaudet, D. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet, 385(9965), 331-340
Open this publication in new window or tab >>PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Show others...
2015 (English)In: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 385, no 9965, p. 331-340Article in journal (Refereed) Published
Abstract [en]

Background Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature cardiovascular disease. Despite intensive statin therapy, with or without ezetimibe, many patients are unable to achieve recommended target levels of LDL cholesterol. We investigated the effect of PCSK9 inhibition with evolocumab (AMG 145) on LDL cholesterol in patients with this disorder. Methods This multicentre, randomised, double-blind, placebo-controlled trial was undertaken at 39 sites (most of which were specialised lipid clinics, mainly attached to academic institutions) in Australia, Asia, Europe, New Zealand, North America, and South Africa between Feb 7 and Dec 19,2013.331 eligible patients (18-80 years of age), who met clinical criteria for heterozygous familial hypercholesterolaemia and were on stable lipid-lowering therapy for at least 4 weeks, with a fasting LDL cholesterol concentration of 2.6 mmol/L or higher, were randomly allocated in a 2:2:1:1 ratio to receive subcutaneous evolocumab 140 mg every 2 weeks, evolocumab 420 mg monthly, or subcutaneous placebo every 2 weeks or monthly for 12 weeks. Randomisation was computer generated by the study sponsor, implemented by a computerised voice interactive system, and stratified by LDL cholesterol concentration at screening (higher or lower than 4.1 mmol/L) and by baseline ezetimibe use (yes/no). Patients, study personnel, investigators, and Amgen study staff were masked to treatment assignments within dosing frequency groups. The coprimary endpoints were percentage change from baseline in LDL cholesterol at week 12 and at the mean of weeks 10 and 12, analysed by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT01763918. Findings Of 415 screened patients, 331 were eligible and were randomly assigned to the four treatment groups: evolocumab 140 mg every 2 weeks (n=111), evolocumab 420 mg monthly (n=110), placebo every 2 weeks (n=55), or placebo monthly (n=55). 329 patients received at least one dose of study drug. Compared with placebo, evolocumab at both dosing schedules led to a significant reduction in mean LDL cholesterol at week 12 (every-2-weeks dose: 59.2% reduction [95% CI 53.4-65.1], monthly dose: 61.3% reduction [53.6-69.0]; both pless than0.0001) and at the mean of weeks 10 and 12 (60.2% reduction [95% CI 54.5-65.8] and 65.6% reduction [59.8-71.3]; both pless than0.0001). Evolocumab was well tolerated, with rates of adverse events similar to placebo. The most common adverse events occurring more frequently in the evolocumab-treated patients than in the placebo groups were nasopharyngitis (in 19 patients [9%] vs five [5%] in the placebo group) and muscle-related adverse events (ten patients [5%] vs 1 [1%]). Interpretation In patients with heterozygous familial hypercholesterolaemia, evolocumab administered either 140 mg every 2 weeks or 420 mg monthly was well tolerated and yielded similar and rapid 60% reductions in LDL cholesterol compared with placebo.

Place, publisher, year, edition, pages
Elsevier: Lancet, 2015
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-114580 (URN)10.1016/S0140-6736(14)61399-4 (DOI)000348509000026 ()
Available from: 2015-02-27 Created: 2015-02-26 Last updated: 2017-12-04
Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I., Olsson, A., . . . Ladenson, P. W. (2015). Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. Journal of Internal Medicine, 277(3), 331-342
Open this publication in new window or tab >>Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome
Show others...
2015 (English)In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 277, no 3, p. 331-342Article in journal (Refereed) Published
Abstract [en]

BackgroundLiver-selective thyromimetic agents could provide a new approach for treating dyslipidaemia. MethodsWe performed a multicentre, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eprotirome, a liver-selective thyroid hormone receptor agonist, in 98 patients with primary hypercholesterolaemia. After previous drug wash-out and dietary run-in, patients received 100 or 200gday(-1) eprotirome or placebo for 12weeks. The primary end-point was change in serum LDL cholesterol; secondary end-points included changes in other lipid parameters and safety measures. ResultsEprotirome treatment at 100 and 200g daily reduced serum LDL cholesterol levels by 235% and 31 +/- 4%, respectively, compared with 2 +/- 6% for placebo (Pless than0.0001). Similar reductions were seen in non-HDL cholesterol and apolipoprotein (apo) B, whereas serum levels of HDL cholesterol and apo A-I were unchanged. There were also considerable reductions in serum triglycerides and lipoprotein(a), in particular in patients with elevated levels at baseline. There was no evidence of adverse effects on heart or bone and no changes in serum thyrotropin or triiodothyronine, although the thyroxine level decreased. Low-grade increases in liver enzymes were evident in most patients. ConclusionIn hypercholesterolaemic patients, the liver-selective thyromimetic eprotirome decreased serum levels of atherogenic lipoproteins without signs of extra-hepatic side effects. Selective stimulation of hepatic thyroid hormone receptors may be an attractive way to modulate lipid metabolism in hyperlipidaemia.

Place, publisher, year, edition, pages
Wiley: 12 months, 2015
Keywords
cholesterol; hypercholesterolaemia; lipoprotein; liver; thyroid
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-116513 (URN)10.1111/joim.12261 (DOI)000349977300005 ()24754313 (PubMedID)
Note

Funding Agencies|Karo Bio

Available from: 2015-03-27 Created: 2015-03-27 Last updated: 2017-12-04
Organisations

Search in DiVA

Show all publications